Yousif Capital Management LLC Sells 218 Shares of Revvity Inc. (NYSE:RVTY)

Yousif Capital Management LLC trimmed its holdings in Revvity Inc. (NYSE:RVTY) by 1.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,917 shares of the company’s stock after selling 218 shares during the quarter. Yousif Capital Management LLC’s holdings in Revvity were worth $1,367,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. lifted its stake in Revvity by 16.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 20,761,308 shares of the company’s stock worth $2,317,170,000 after purchasing an additional 2,969,326 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Revvity by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 14,290,211 shares of the company’s stock worth $1,594,930,000 after acquiring an additional 156,679 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Revvity by 17.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,631,597 shares of the company’s stock worth $851,764,000 after acquiring an additional 1,151,821 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Revvity by 0.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,358,952 shares of the company’s stock worth $709,725,000 after acquiring an additional 23,650 shares during the last quarter. Finally, EdgePoint Investment Group Inc. lifted its position in shares of Revvity by 51.1% during the fourth quarter. EdgePoint Investment Group Inc. now owns 4,058,231 shares of the company’s stock worth $452,939,000 after purchasing an additional 1,372,456 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Stock Performance

Shares of RVTY opened at $94.22 on Wednesday. The company has a 50-day simple moving average of $93.15 and a 200-day simple moving average of $106.51. The company has a quick ratio of 2.99, a current ratio of 3.58 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $11.11 billion, a PE ratio of 40.09, a P/E/G ratio of 2.35 and a beta of 0.97. Revvity Inc. has a 52-week low of $87.70 and a 52-week high of $129.50.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.05. Revvity had a return on equity of 7.73% and a net margin of 10.35%. The firm had revenue of $664.76 million during the quarter, compared to the consensus estimate of $662.30 million. During the same period last year, the business posted $0.98 EPS. Revvity’s quarterly revenue was up 2.3% on a year-over-year basis. Equities research analysts predict that Revvity Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date is Friday, July 18th. Revvity’s dividend payout ratio (DPR) is presently 11.91%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on RVTY shares. Raymond James Financial reiterated an “outperform” rating and set a $120.00 price objective (down previously from $145.00) on shares of Revvity in a report on Tuesday, April 29th. Robert W. Baird decreased their price target on shares of Revvity from $127.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, April 29th. The Goldman Sachs Group decreased their target price on Revvity from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 29th. Wells Fargo & Company decreased their target price on Revvity from $130.00 to $102.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Finally, JPMorgan Chase & Co. decreased their price objective on Revvity from $120.00 to $100.00 and set a “neutral” rating for the company in a report on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $125.64.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.